Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Index- P/E27.45 EPS (ttm)1.80 Insider Own- Shs Outstand2.66B Perf Week-3.59%
Market Cap131.30B Forward P/E15.42 EPS next Y3.21 Insider Trans- Shs Float2.37B Perf Month-0.30%
Income4.77B PEG4.69 EPS next Q- Inst Own9.90% Short Float0.06% Perf Quarter4.50%
Sales38.63B P/S3.40 EPS this Y18.80% Inst Trans2.62% Short Ratio1.04 Perf Half Y7.15%
Book/sh23.83 P/B2.07 EPS next Y3.05% ROA4.50% Target Price56.60 Perf Year-4.17%
Cash/sh3.16 P/C15.63 EPS next 5Y5.85% ROE7.80% 52W Range42.16 - 55.57 Perf YTD11.94%
Dividend1.62 P/FCF- EPS past 5Y-4.00% ROI7.00% 52W High-11.08% Beta0.98
Dividend %3.28% Quick Ratio1.30 Sales past 5Y1.80% Gross Margin67.80% 52W Low17.18% ATR0.93
Employees113496 Current Ratio1.80 Sales Q/Q12.20% Oper. Margin19.60% RSI (14)47.24 Volatility1.83% 1.40%
OptionableYes Debt/Eq0.26 EPS Q/Q-6.50% Profit Margin12.50% Rel Volume1.31 Prev Close50.55
ShortableYes LT Debt/Eq0.24 EarningsApr 30 BMO Payout47.50% Avg Volume1.38M Price49.41
Recom1.70 SMA20-1.20% SMA50-0.56% SMA2001.97% Volume1,813,229 Change-2.26%
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
May-29-15 04:53PM  R&D Can Be A Critical Factor In Generating Future Profits
11:43AM  Rare But Severe Facial Damage With Soft-Tissue Dermal Fillers, FDA Warns at Forbes
May-28-15 02:07PM  These dozen Mass. companies are honed in on drugs for rare diseases (BBJ photo gallery) at
01:56PM  Moody's: High barriers to entry spur M&A activity in orphan drug sector at Moody's
10:22AM  Sanofi Announces Men With Advanced Prostate Cancer in England Will Continue to Have Access to Cabazitaxel (Jevtana®) PR Newswire
May-27-15 09:18AM  Retrophin Sells FDA Voucher to Sanofi at The Wall Street Journal
06:00AM  Genzyme Commemorates World MS Day with Awareness and Educational Events Globally Business Wire
May-26-15 08:00AM  Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC Business Wire
04:30AM  NeuroVive Asia Signs Collaboration Agreement with Sanofi for the Development and Commercialization of Ciclomulsion® in South Korea Business Wire
01:00AM  Fight over hot new cholesterol drugs may be won in milligrams Reuters
May-25-15 09:00AM  Prince Edward Island funds treatment with AUBAGIO(TM) for Relapsing Remitting Multiple Sclerosis CNW Group
May-22-15 04:20PM  Sanofis Global Head for Prostate Drug, Zhen Su, Leaves Company at Bloomberg
01:23PM  In Massachusetts, biotech firms account for a lot of value but few jobs at
07:23AM  Amgen first to win EU backing for new kind of cholesterol drug Reuters
May-21-15 04:27PM  3 Top IBD 50 Stocks Hit New All-Time Highs
10:30AM  Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog
01:00AM  Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis PR Newswire
May-20-15 07:00AM  Genzymes Announces Launch of Expression of Hope III Art Exhibit Business Wire
06:58AM  Orexigen CEO Pledged To Keep Data Secret, But Not From Himself at Forbes
May-19-15 04:40PM  Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog
03:13PM  MannKind stock jumps on positive report about inhaled insulin at Los Angeles Times
12:04PM  Amgen cholesterol drug could get EU green light this week Reuters
11:00AM  VCEL: Vericel Is Too Cheap To Ignore
08:53AM  5 Big Pharma Stocks to Trade for Breakout Gains at TheStreet
08:00AM  Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the Development of Cerdelga® Business Wire
01:40AM  MannKind's Huge Short Interest Sets Up Contrarian's Dream Buy at Forbes
May-18-15 04:21PM  Healthcare Winners and Losers: May 18, 2015
12:30PM  Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference PR Newswire
May-15-15 04:19PM  5 Things MannKind's Management Wants You to Know at Investopedia
May-14-15 04:45PM  Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog
May-13-15 11:00AM  Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog
07:00AM  Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology Business Wire
May-11-15 03:35PM  MannKind 'Facing Low Profitability And Delayed Profits' As Afrezza Ramp Fizzles, Goldman Says
11:16AM  MannKind: 'Early Launch Struggles Could Be Difficult to Overcome' at
09:29AM  Buy Warren Buffett's 5 Highest-Yielding Dividend Stocks for Income Now at TheStreet
08:30AM  Singer and "Pretty Little Liars" Actress Lucy Hale Lends Her Voice to Voices of Meningitis to Help Improve Teen Booster Vaccination Rates PR Newswire
May-08-15 12:00PM  MannKind's (MNKD) Q1 Loss In Line with Expectation - Analyst Blog
11:30AM  POZN: For Pozen, 'The Waiting' Is The Hardest Part
11:23AM  Five Reasons MannKind's Q1 Performance Rang Loud Alarm Bells at TheStreet
11:03AM  Industrial Production in France Shows Strength in Recovery
11:00AM  What to Make of MannKind Earnings at 24/7 Wall St.
May-07-15 04:05PM  Keryx CEO 'pleased' with drug launch as firm expands in Boston at
01:31PM  Regeneron Pharmaceuticals (REGN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
May-06-15 06:08PM  Today's Top 5 Stock Picks: Undervalued Large-Caps at
06:00AM  Hot Drugs Show Sharp Price Hikes in Shadow Market
06:00AM  Diabetes Drugs Compete With Prices That Rise in Lockstep at Bloomberg
May-05-15 09:00AM  Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives PR Newswire
09:00AM  Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives CNW Group
07:36AM  L'Oreal S.A. -- Moody's affirms L'Oreal S.A.'s Prime-1 rating at Moody's
May-04-15 01:07PM  Sanofi: Annual General Shareholder Meeting of May 4, 2015 at noodls
12:31PM  Sanofi rebels make mark in AGM vote on CEO pay
May-01-15 10:55AM  Sanofi Misses on Q1 Earnings by a Penny, Maintains Outlook - Analyst Blog
09:02AM  Will Sanofi's Big Bet On Vaccines Pull It Out Of Its Diabetes Slump? at Forbes
Apr-30-15 05:17PM  Early sales of MannKind inhaled insulin drug disappoint Wall Street at Los Angeles Times
03:22PM  Sanofi faces AGM row over cost of firing and hiring CEOs Reuters
02:56PM  Biotech boom land grab
11:50AM  Pharma: No standout performers
08:50AM  Potential Peninsula biotech IPO lands $46 million at
07:53AM  Sanofi Delivers Q1 2015 Business EPS Growth of 2.6% at CER and 12.8% on a Reported Basis PR Newswire
07:35AM  Sanofi Says Diabetes Revenue to Fall at The Wall Street Journal
07:08AM  European drugmakers lifted by weak euro at Financial Times
06:51AM  MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales at TheStreet
06:29AM  UPDATE 2-Sanofi warns of lower diabetes drug sales this year
04:35AM  Drugmaker Sanofi sees Q1 profit drop amid leadership change
01:52AM  Sanofi Q1 2015 Results - Interview With CFO Jérôme Contamine PR Newswire
01:42AM  Sanofi keeps 2015 guidance with steady Q1 profits
01:30AM  Sanofi Diabetes Sales Drop After Lantus Gets Price Cut in U.S. at Bloomberg
12:43AM  Sanofi delivers Q1 2015 Business EPS(1) growth of 2.6% at CER(2) and 12.8% on a reported basis ACN Newswire
Apr-29-15 06:18PM  Sanofi's (SNY) Basal Insulin Toujeo Gains European Approval - Analyst Blog
03:34PM  Januvia Passes, Afrezza On Deck at Forbes
01:18PM  Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings at TheStreet
Apr-28-15 04:10PM  Partners looks to commercialize innovation with international forum at
09:38AM  Sanofi: Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults at noodls
01:22AM  Sanofi says U.S. FDA to fast track Fabry therapy review Reuters
01:17AM  Sanofi: FDA Grants Fast Track Designation to Genzyme's Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease at noodls
01:00AM  FDA Grants Fast Track Designation to Genzymes Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease Business Wire
Apr-27-15 05:11PM  More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes at Forbes
03:02PM  ImmunoGen skids after disclosing drug development setbacks
10:17AM  Synta Pharmaceuticals names third CEO since March 2014 at
Apr-23-15 09:04AM  Sanofi: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years at noodls
09:00AM  Effect of Genzymes Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years Business Wire
Apr-22-15 02:02PM  Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog
01:50PM  How a Stronger US Dollar Has Affected Large-Cap Stocks
11:43AM  Amgen: But What About the Biosimilars? at
06:39AM  Sanofi-Aventis upgraded by Citigroup
Apr-21-15 09:00AM  Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease Business Wire
Apr-17-15 10:44AM  Bristol's Opdivo Scores Again Against Lung Cancer at Investor's Business Daily
Apr-16-15 12:00PM  Actelion to Boost Progress of Specialty Immunology Pipeline - Analyst Blog
Apr-14-15 07:06PM  The Medicines Co.'s Kengreal Briefing Documents Positive - Analyst Blog
Apr-13-15 05:00PM  Fewer CEOs Fired and More Retired Save Shareholders Billions at Bloomberg
05:00PM  Fewer CEOs Are Being Fired and That's Good News for Shareholders
02:10PM  Wave of interest in gene therapy brings Voyager a new $60M investment at
09:00AM  Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN Business Wire
Apr-10-15 08:30AM  Trade Europe and a Strong USD with this ETF at Investopedia
Apr-09-15 10:51AM  Inverse Head and Shoulders Patterns Breaking Out at Investopedia
Apr-08-15 02:03PM  What Really Happens To Stocks When The Fed Tightens Monetary Policy? at Forbes
Apr-07-15 01:30PM  Sanofi: Shantha will provide up to 37 million doses of Shan5(TM) at noodls
01:30PM  Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide) at noodls
01:30PM  Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine at noodls
12:19AM  [$$] Bristol-Myers Invests in Dutch Company uniQure at The Wall Street Journal
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM
Sanofi10% OwnerJul 03Buy311.02100,00031,101,94620,996,041Jul 08 05:42 PM
Sanofi10% OwnerJul 02Buy307.25212,40065,259,55220,896,041Jul 03 06:00 PM
Sanofi10% OwnerJul 01Buy300.20212,40063,761,42120,683,641Jul 03 05:46 PM
Sanofi10% OwnerJun 30Buy282.54212,40060,010,47920,471,241Jul 01 05:39 PM
Sanofi10% OwnerJun 27Buy275.3850,00013,769,09220,258,841Jul 01 05:39 PM